Clinical Trial

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-10-16; most recent amendment 2026-03-19.
Trial Details
NCT Number NCT07218601
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Non-Small Cell Lung Cancer
Enrollment 60 participants
Start Date 2025-10-10
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-23